DelveInsight has launched a report on “Polycythemia Vera – Market Insights, Epidemiology, and Market Forecast-2030”
DelveInsight’s “Polycythemia Vera – Market Insights, Epidemiology, and Market Forecast-2030“ report delivers an in-depth understanding of the Polycythemia Vera , historical and forecasted epidemiology as well as the Polycythemia Vera market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the Facts:
Key facts of the report:
“As per DelveInsight’s analysis, the therapeutic market of Polycythemia Vera (PV) in the seven major markets was assessed to be USD 1,099.54 million in 2017”
Polycythemia Vera (PV) is a rare condition characterized by the progressively increased number of red blood cells in bloodstream, white blood cells (WBC) and platelets also increase in number in the affected people. This condition is known as myeloproliferative neoplasms, where the body produces too many of these cells (RBC, WBC and Platelets). These new cells cause the blood to be thicker than usual, increasing the risk for blood clots that can block blood flow in arteries and veins. If a blood clot occurs in the veins, deep in the arms and the legs, it is known as deep vein thrombosis (DVT).
Mutation in the JAK2 kinase is responsible for PV. Most cases of PV are associated with genetic changes that are somatic, not in the egg and sperm cells, which pass on genetic information to offspring.
The diagnosis of PV is done by testing the blood for levels of a hormone called erythropoietin or testing the blood for mutations in JAK2. Bone marrow aspiration and biopsy are also done to confirm whether or not a person has PV. The diagnostic test also includes Complete blood count (CBC) to measure the number and quality of WBCs, RBCs, and platelets.
Request for Sample Pages: https://www.delveinsight.com/sample-request/polycythemia-vera-market
Some of the key companies working on Polycythemia Vera are:
And Many Others.
The launch of the emerging therapies is expected to significantly impact the Polycythemia Vera treatment scenario in the upcoming years:-
Drugs Covered:
And Many Others
Table of Contents:
3.1. Market (%) Distribution of PV in 2017
3.2. Market (%) Distribution of PV in 2030
4.1. Introduction
4.2. Polycythemia Vera: A Type of MPN
4.3. Signs and Symptoms of Polycythemia Vera
4.4. Causes of Polycythemia Vera
4.5. Complications due to Polycythemia Vera
4.6. Clinical Aspects of Polycythemia Vera
4.7. Pathophysiology of Polycythemia Vera
4.7.1. JAK2 V617F in Polycythemia Vera
4.8. Diagnosis of Polycythemia Vera
4.9. Diagnostic Guidelines
4.9.1. British Society for Hematology Guidelines for Polycythemia Vera (PV)
4.9.2. WHO Diagnostic Guidelines
4.9.3. British Society for Hematology Guideline
6.1. Methodology
6.2. Key Findings
6.3. Total Prevalent Population of Polycythemia Vera in the 7MM
6.4. Total Diagnosed Prevalent Population of Polycythemia Vera in the 7MM
6.6. Age-Specific Diagnosed Prevalence of Polycythemia Vera in the 7MM
6.7. Diagnosed Prevalence of Polycythemia Vera by Gene Mutation in the 7MM
7.1. Assumptions and Rationale
7.2. KOL Insights
7.3. Total Prevalent Population of Polycythemia Vera in the United States
7.4. Total Diagnosed Prevalent Population of Polycythemia Vera in the United States
7.5. Gender-Specific Diagnosed Prevalence of Polycythemia Vera in the United States
7.7. Diagnosed Prevalence of PV by Gene Mutation in the United States
8.1. Germany Epidemiology
8.1.1. Assumptions and Rationale
8.1.2. Total Prevalent Population of Polycythemia Vera in Germany
8.1.3. Total Diagnosed Prevalent Population of Polycythemia Vera in Germany
8.1.4. Gender-Specific Diagnosed Prevalence of Polycythemia Vera in Germany
8.1.5. Age-Specific Diagnosed Prevalence of Polycythemia Vera in Germany
8.1.6. Diagnosed Prevalence of PV by Gene Mutation in Germany
8.2. France Epidemiology
8.2.1. Assumptions and rationale
8.2.2. Total Prevalent Population of Polycythemia Vera in France
8.2.3. Total Diagnosed Prevalent Population of Polycythemia Vera in France
8.2.4. Gender-Specific Diagnosed Prevalence of Polycythemia Vera in France
8.2.5. Age-Specific Diagnosed Prevalence of Polycythemia Vera in France
8.3. Italy Epidemiology
8.3.1. Assumptions and Rationale
8.3.2. Total Prevalent Population of Polycythemia Vera in Italy
8.3.3. Total Diagnosed Prevalent Population of Polycythemia Vera in Italy
8.3.4. Gender-Specific Diagnosed Prevalence of Polycythemia Vera in Italy
8.3.5. Age-Specific Diagnosed Prevalence of Polycythemia Vera in Italy
8.3.6. Diagnosed Prevalence of PV by Gene Mutation in Italy
8.4. Spain Epidemiology
8.4.1. Assumptions and Rationale
8.4.2. Total Prevalent Population of Polycythemia Vera in Spain
8.4.3. Total Diagnosed Prevalent Population of Polycythemia Vera in Spain
8.4.4. Gender-Specific Diagnosed Prevalence of Polycythemia Vera in Spain
8.4.5. Age-Specific Diagnosed Prevalence of Polycythemia Vera in Spain
8.4.6. Diagnosed Prevalence of PV by Gene Mutation in Spain
8.5. United Kingdom Epidemiology
8.5.1. Assumptions and Rationale
8.5.2. Total Prevalent Population of Polycythemia Vera in the United Kingdom
8.5.3. Total Diagnosed Prevalent Population of Polycythemia Vera in the United Kingdom
8.5.5. Age-Specific Diagnosed Prevalence of Polycythemia Vera in the United Kingdom
8.5.6. Diagnosed Prevalence of PV by Gene Mutation in the United Kingdom
8.6. KOL Insights
9.1. Assumptions and Rationale
9.2. KOL Insights
9.3. Total Prevalent Population of Polycythemia Vera in Japan
9.4. Total Diagnosed Prevalent Population of Polycythemia Vera in Japan
9.5. Gender-Specific Diagnosed Prevalence of Polycythemia Vera in Japan
9.6. Age-Specific Diagnosed Prevalence of Polycythemia Vera in Japan
9.7. Diagnosed Prevalence of PV by Gene Mutation in Japan
10.1. Treatment Algorithm
10.2. Proposed Guidelines for Polycythemia Vera
10.2.1. A British Society for Haematology Guidelines for PV
10.2.2. National Comprehensive Cancer Network (NCCN) Guidelines for Polycythemia Vera (PV)
10.2.3. European Society for Medical Oncology Guidelines for Polycythemia Vera
12.1. Jakafi (Ruxolitinib): Incyte Corporation/Novartis
12.1.1. Drug Description
12.1.2. Regulatory Milestones
12.1.3. Clinical Development
12.1.4. Safety and Efficacy
12.1.5. Product Description
12.2. Besremi: AOP Orphan Pharmaceuticals AG/ PharmaEssentia
12.2.1. Product Description
12.2.2. Mechanism of Action
12.2.3. Regulatory Milestones
12.2.4. Advantages and Disadvantages
12.2.5. Clinical Development
12.2.6. Safety and Efficacy
12.2.7. Product Profile
13.1. Key Cross Competition
13.2. Idasanutlin: Hoffmann-La Roche
13.2.1. Product Description
13.2.2. Other Developmental Activities
13.2.3. Advantages and Disadvantages
13.2.4. Clinical Development
13.2.5. Clinical Trials Information
13.2.6. Safety and Efficacy
13.2.7. Product Profile
13.3. KRT-232: Kartos Therapeutics
13.3.1. Product Description
13.3.2. Clinical Development
13.3.3. Clinical Trials Information
13.3.4. Product Profile
13.4. Givinostat: Italfarmaco
13.4.1. Product Description
13.4.2. Other Developmental Activities
13.4.3. Advantages and Disadvantages
13.4.4. Clinical Development
13.4.5. Clinical Trials Information
13.4.6. Safety and Efficacy
13.4.7. Product Profile
List to be continued in the report………
14.1. Key Findings
14.2. Market Size of Polycythemia Vera in 7MM
14.3. Market Size of Polycythemia Vera by Therapies in the 7MM
15.1. United States Market Size
15.1.1. Total Market size of Polycythemia Vera in the United States
15.1.2. Market Size of Polycythemia Vera by Therapies in the US
16.1. Germany Market Size
16.1.1. Total Market size of Polycythemia Vera in Germany
16.1.2. Market Size of Polycythemia Vera by therapies in Germany
16.2. France Market Size
16.2.1. Total Market size of Polycythemia Vera in France
16.2.2. Market Size of Polycythemia Vera by therapies in France
16.3. Italy Market Size
16.3.1. Total Market size of Polycythemia Vera in Italy
16.3.2. Market Size of Polycythemia Vera by therapies in Italy
16.4. Spain Market Size
16.4.1. Total Market size of Polycythemia Vera in Spain
16.4.2. Market Size of Polycythemia Vera by therapies in Spain
16.5. United Kingdom Market Size
16.5.1. Total Market size of Polycythemia Vera in the United Kingdom
16.5.2. Market Size of Polycythemia Vera by therapies in the UK
17.1. Japan Market Size
17.1.1. Total Market size of Polycythemia Vera in Japan
17.1.2. Market Size of Polycythemia Vera by therapies in Japan
19.1. Report Methodology
Related Reports:
Polycythemia Vera – Pipeline Insights, 2020
The Polycythemia Vera report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Polycythemia Vera across the complete product development cycle, including all clinical and nonclinical stages.
Polycythemia Vera – Epidemiology Forecast to 2030
The Polycythemia Vera epidemiology covered in the report provides historical as well as forecasted Polycythemia Vera epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/